Business
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
-- Rett syndrome research to include oral presentation of Phase 3 Lavender trial and poster presentation highlighting the patient journey and clinical burden
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n-- Rett syndrome research to include oral presentation of Phase 3 Lavender trial and poster presentation highlighting the patient journey and clinical burden of the disease\n\n-- E-poster presentation evaluating maintenance of efficacy and safety of pimavanserin among patients with Parkinson’s disease dementia with psychosis\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.\n\n“We look forward to the upcoming presentation of the Phase 3 Lavender results at this year’s AAN and the opportunity to educate neurologists on the critical unmet need that exists for patients and their caregivers living with this rare and serious neurological disease,” said Kathie Bishop, Ph.D., Acadia’s Senior Vice President, Chief Scientific Officer and Head of Rare Disease.\n\nAAN Accepted Presentations and Posters:\n\nEmerging Science (Late-Breaker):\n\n\nOral Presentation: Efficacy and safety of trofinetide for the treatment of Rett syndrome: results from the pivotal phase 3 Lavender study.\nTuesday, April 5, from 9:15 a.m. - 11:30 a.m.\n\n\nPosters:\n\n\nPoster # 001: Patient journey and clinical burden of Rett syndrome in the United States: research study including nearly 6,000 girls provides an overview of the patient journey and clinical burden of RTT with respect to baseline characteristics, clinical manifestations and treatment patterns among female individuals in the US.\nTuesday, April 5, from 11:45 a.m. - 12:45 p.m.\n\n\n\nE-Poster # P1.006: Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the Phase 3 HARMONY clinical trial. Analysis evaluating the maintenance of efficacy, as measured by time to relapse, of pimavanserin in a subgroup of patients with Parkinson’s disease dementia with psychosis during the 26-week maintenance phase of the HARMONY clinical trial.\nVirtual American Academy of Neurology Annual Meeting, April 24-26.\n\n\nAbout Rett Syndrome\n\nRett syndrome is a rare, debilitating neurological disorder th...